Cytokine expression and microglial activation in progressive supranuclear palsy

Parkinsonism and Related Disorders

Volumn 17, Issue 9, 2011, Pages 683-688

  Fernández Botrán, Rafael ^a   Ahmed, Zeshan ^b   Crespo, Fabián A ^c   Gatenbee, Chandler ^a   Gonzalez, John ^b   Dickson, Dennis W ^b   Litvan, Irene ^a  

^a University of Louisville School of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Alzheimer's disease; Brain; Cytokines; Inflammation; Microglia; Progressive supranuclear palsy

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; CAUDATE NUCLEUS; CELL ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DISEASE COURSE; ENCEPHALITIS; FEMALE; FRONTAL LOBE; GENE CONTROL; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; MALE; MICROGLIA; PARIETAL CORTEX; PARIETAL LOBE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

AGED; BRAIN; CYTOKINES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 80054855155     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.06.007     Document Type: Article

References (30)

1. Litvan I. Update on progressive supranuclear palsy. Curr Neurol Neurosci Rep 2004, 4:296-302.
2. Williams D.R., Lees A.J. Progressive supranuclear plasy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009, 8:270-279.
3. Schrag A., Ben-Shlomo Y., Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999, 354:1771-1775.
4. Hauw J.J., Daniel S.E., Dickson D., Horoupian D.S., Jellinger K., Lantos P.L., et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994, 44:2015-2019.
5. Ishizawa K., Dickson D.W. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 2001, 60:647-657.
6. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - A double-edged sword. Neuron 2002, 35:419-432.
7. Dheen S.T., Kaur C., Ling E.A. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007, 14:1189-1197.
8. Block M.L., Hong J.S. Microglia and inflammation-mediated neuro-degeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005, 76:77-98.
9. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439.
10. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener 2009, 4:47-60.
11. Allan S.M., Tyrrell P., Rothwell N.J. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005, 5:629-640.
12. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208-210.
13. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994, 172:151-154.
14. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., et al. Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994, 180:147-150.
15. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995, 21:195-218.
16. Fujishiro H., Ferman T.J., Boeve B.F., Smith G.E., Graff-Radford N.R., Uitti R.J., et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008, 67:649-656.
17. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., et al. The RIN: an RNA integrity number for assessing integrity values to RNA measurements. BMC Mol Biol 2006, 7:3.
18. Barber R.D., Harmer D.W., Coleman R.A., Clark B.J. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005, 21:389-395.
19. Li Y., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003, 23:1605-1611.
20. Nicoll J.A.R., Mrak R.E., Graham D.I., Stewart J., Wilcock G., MacGowan S., et al. Association of interleukin-1 (IL-1) gene polymorphisms with Alzheimer's disease. Ann Neurol 2000, 47:365-368.
21. Grammas P., Ovase R. Cerebrovascular transforming growth factor-β contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 2002, 160:1583-1587.
22. Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature 1997, 389:603-606.
23. Kim W.K., Hwang S.Y., Oh E.S., Piao H.Z., Kim K.W., Han I.O. TGF-β1 represses activation and resultant death of microglia via inhibition of phosphatidylinositol 3-kinase activity. J Immunol 2004, 172:7015-7023.
24. Town T., Laouar Y., Pittenger C., Szekely C.A., Tan J., Duman R.S., et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14:681-687.
25. Lippa C.F., Flanders K.C., Kim E.S., Croul S. TGF-beta receptors-I and -II immunoexpression in Alzheimer's disease: a comparison with aging and progressive supranuclear palsy. Neurobiol Aging 1998, 19:527-533.
26. Chantry D., Turner M., Abney E., Feldmann M. Modulation of cytokine production by transforming growth factor-β. J Immunol 1989, 142:4295-4300.
27. Bogdan C., Paik J., Vodovotz Y., Natham C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem 1992, 267:23301-23308.
28. Wahl S.M. Transforming growth factor β: the good, the bad and the ugly. J Exp Med 1994, 180:1587-1590.
29. Ervin J.F., Heinzen E.L., Cronin K.D., Goldstein D., Szymanski M.H., Burke J.R., et al. Postmortem delay has minimal effect on brain RNA integrity. J Neuropathol Exp Neurol 2007, 66:1093-1099.
30. Bennet D.A., Whitmer R.A. NSAID exposure and risk of Alzheimer's disease. Is timing everything?. Neurology 2009, 72:1884-1885.